For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
As of close of business last night, Corcept Therapeutics Inc’s stock clocked out at $68.82, down -2.15% from its previous closing price of $70.33. In other words, the price has decreased by -$2.15 from its previous closing price. On the day, 0.88 million shares were traded. CORT stock price reached its highest trading level at $70.82 during the session, while it also had its lowest trading level at $68.77.
Ratios:
To gain a deeper understanding of CORT’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 21.19 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 40.22. For the most recent quarter (mrq), Quick Ratio is recorded 2.98 and its Current Ratio is at 3.06. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Truist on November 06, 2023, Upgraded its rating to Buy and sets its target price to $38 from $29 previously.
On April 11, 2023, SVB Securities started tracking the stock assigning a Market Perform rating and target price of $25. On April 04, 2023, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $27.Piper Sandler initiated its Overweight rating on April 04, 2023, with a $27 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 22 ’25 when Robb Gary Charles bought 2,326 shares for $71.27 per share.
Swisher Daniel N JR sold 2,200 shares of CORT for $159,060 on Aug 11 ’25. The Director now owns 0 shares after completing the transaction at $72.30 per share. On Aug 08 ’25, another insider, Guyer William, who serves as the Chief Development Officer of the company, sold 35,007 shares for $71.77 each. As a result, the insider received 2,512,452 and left with 5,487 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CORT now has a Market Capitalization of 7251701248 and an Enterprise Value of 7075172864. As of this moment, Corcept’s Price-to-Earnings (P/E) ratio for their current fiscal year is 61.24, and their Forward P/E ratio for the next fiscal year is 31.57. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.95. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.13 while its Price-to-Book (P/B) ratio in mrq is 11.40. Its current Enterprise Value per Revenue stands at 9.88 whereas that against EBITDA is 68.945.
Stock Price History:
The Beta on a monthly basis for CORT is 0.29, which has changed by 0.9855741 over the last 52 weeks, in comparison to a change of 0.14460516 over the same period for the S&P500. Over the past 52 weeks, CORT has reached a high of $117.33, while it has fallen to a 52-week low of $33.34. The 50-Day Moving Average of the stock is -3.17%, while the 200-Day Moving Average is calculated to be 5.26%.
Shares Statistics:
It appears that CORT traded 1.22M shares on average per day over the past three months and 624890 shares per day over the past ten days. A total of 105.29M shares are outstanding, with a floating share count of 93.24M. Insiders hold about 11.51% of the company’s shares, while institutions hold 75.35% stake in the company. Shares short for CORT as of 1753920000 were 11045208 with a Short Ratio of 9.03, compared to 1751241600 on 11446765. Therefore, it implies a Short% of Shares Outstanding of 11045208 and a Short% of Float of 14.16.
Earnings Estimates
The current assessment of Corcept Therapeutics Inc (CORT) involves the perspectives of 4.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is $0.44, with high estimates of $0.71 and low estimates of $0.31.
Analysts are recommending an EPS of between $1.38 and $0.8 for the fiscal current year, implying an average EPS of $1.08. EPS for the following year is $2.18, with 4.0 analysts recommending between $3.31 and $0.77.
Revenue Estimates
In the current quarter, 4 analysts expect revenue to total $223.78M. It ranges from a high estimate of $240M to a low estimate of $210.12M. As of the current estimate, Corcept Therapeutics Inc’s year-ago sales were $182.55MFor the next quarter, 4 analysts are estimating revenue of $289.05M. There is a high estimate of $313.23M for the next quarter, whereas the lowest estimate is $275.9M.
A total of 4 analysts have provided revenue estimates for CORT’s current fiscal year. The highest revenue estimate was $875M, while the lowest revenue estimate was $852.5M, resulting in an average revenue estimate of $864.45M. In the same quarter a year ago, actual revenue was $675.04MBased on 4 analysts’ estimates, the company’s revenue will be $1.19B in the next fiscal year. The high estimate is $1.38B and the low estimate is $1.01B.
